CL

Business profile & competitive position

Colgate-Palmolive is classified as a Consumer Defensive company in the Household & Personal Products industry, meaning it makes everyday consumables with repeat-purchase demand rather than cyclical discretionary goods. The business model rests on brand recognition, shelf presence, and pricing power in categories such as oral care, personal cleaning, and household products.

The latest profitability figures paint a mixed but instructive picture of its competitive moat. The net margin is 9.7%, a respectable but not dominant level for a branded staples operator; it signals pricing power and cost discipline, yet also shows this is a category where private-label competition and promotional spending keep margins from ballooning. Return on equity is reported at 631.1%, an extreme figure that cannot be read as pure operating-quality premium. In capital-light, heavily repurchasing consumer staples businesses, an ROE this high usually reflects a shrunken equity base from buybacks and leverage rather than a nearly seven-fold annual return on the underlying economics. Pairing that ROE with the 9.7% net margin and a beta of 0.32 suggests the company is viewed as a low-volatility, defensive cash-flow generator whose returns to shareholders are amplified by balance-sheet structure as much as by organic pricing power.

Financial posture

Colgate-Palmolive currently trades with a market capitalization of $74.6 billion and a price-to-earnings ratio of 36.7. For a Consumer Defensive staples name, that multiple sits toward the upper end historically, implying that the market is already baking in continued earnings growth and margin expansion rather than a turnaround story.

The same data set shows a 9.7% net margin and a 0.32 beta. The low beta confirms the stock's defensive character, but the 36.7 P/E against the 9.7% margin means the valuation is not being driven by a high absolute margin profile; it is being driven by expectations of stability, capital returns, and gradual margin improvement. The 631.1% ROE, as noted, is structurally distorted and should be cross-checked with return on invested capital and net debt levels before treating it as evidence of an unusually wide moat. In short, the financial posture is one of a premium-priced defensive operator whose headline metrics look stronger than the underlying business economics suggest.

Macro & geopolitical exposure

As a Household & Personal Products multinational, Colgate-Palmolive sits on the more recession-resistant side of the economy, but it is not immune to macro pressures. The sector is exposed to commodity input costs such as palm oil, petroleum-derived packaging, surfactants, and resins; freight and logistics costs; and wage inflation throughout manufacturing and distribution.

Because these companies generate substantial revenue outside the United States, currency translation is a recurring factor, with a stronger U.S. dollar pressuring reported earnings and a weaker dollar providing a tailwind. Regulatory risk also runs through the industry: rules on product ingredients, sustainability claims, plastic packaging, and chemical safety can force formulation or packaging changes. Trade policy matters through tariffs on imported raw materials or finished goods, while mature-market competition from private labels and local brands can limit volume growth. These exposures are standard for the industry, not company-specific shocks, and they help explain why margin expansion is a recurring theme in management commentary.

Recent developments

On July 31, 2026, GuruFocus reported that the Q2 2026 earnings call highlighted "Strong Organic Growth and Margin Expansion Amid US Challenges." That same day, the company reported actual EPS of $0.99 versus an estimate of $0.947, a 4.5% beat. Despite the beat, the stock slipped 1.56% the next session, illustrating how a strong operating quarter can still be met with selling if expectations are already elevated.

On August 5, 2026, Seeking Alpha published "Colgate-Palmolive: The Reasons I Am Still Not A Buyer After The Q2 Results," reflecting the valuation skepticism embedded in that 36.7 P/E. On August 9, 2026, Fool.com reported that director John Cahill sold 4,170 shares for $389,353; the dollar value is small relative to the $74.6 billion market cap, but it is one of the more visible insider-activity data points around the recent quarter. Also on July 31, 2026, Fool.com asked whether passive-income investors should buy Colgate-Palmolive stock, underscoring the stock's appeal as a dividend-oriented holding even as valuation debates persist.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Colgate-Palmolive has beaten earnings estimates 8 times out of 8, a 100% beat rate, with an average earnings surprise of 3.3%. The average five-day price move after earnings across those quarters is +2.32%, classified as an upward drift.

The recent quarter-by-quarter picture shows the same pattern in finer detail. For the four most recent reports: on July 31, 2026, EPS came in at $0.99 versus $0.947 (4.5% surprise), with the stock down 1.56% the next day but up 2.16% over the following five days; on May 1, 2026, EPS was $0.97 versus $0.943 (2.9% surprise), with a -2.17% next-day move and a +0.33% five-day drift; on January 30, 2026, EPS was $0.95 versus $0.912 (4.2% surprise), with a +1.77% next-day move and a +4.56% five-day drift; and on October 31, 2025, EPS was $0.91 versus $0.889 (2.4% surprise), with the stock down 2.69% the next day but up 2.22% over the next five sessions.

The takeaway from this history is that beats have become the baseline expectation rather than a positive surprise. Three of the last four reports saw immediate selling pressure, yet all four produced positive five-day drift, consistent with the longer-run +2.32% average. The next report is scheduled for October 30, 2026, before the market open, with a consensus EPS estimate of $0.92. At a current price of $93.26, the RSI sits at 54.4, near neutral, and the stock is trading above its 50-day EMA of $91.30.

For a deeper look at how sell-side and quantitative models are currently weighing these factors, review the full institutional verdict on Colgate-Palmolive to see the latest analyst ratings, estimate revisions, and valuation assumptions.